Annovis Bio, Inc. Announces Proposed Public Offering
Article contentMALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug…
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its…